Factor VII F7 Antibodies
Affinity Biologicals, Inc. manufactures a broad range of Factor VII F7 Antibodies which can be found in the listing below. Further information about each individual Factor VII antibody is available by following the associated links. Our Factor VII F7 Antibodies are excellent for use in immunoassays where high sensitivity is required and are frequently the preferred reagent for immunopreciptaion techniques and activity neutralization assays. These antibodies have proven to be extremely useful in the preparation of immune-adsorbent resins for use in immuno-depletion of specific proteins from plasma as well as immuno-affinity purification of proteins. Affinity’s Factor VII F7 Antibodies are manufactured for use in research applications.
Listing of Factor VII F7 Antibodies
SAFVII-IG – Sheep anti human Factor VII, purified IgG (10mg vial)
SAFVII-HRP – Sheep anti human Factor VII, peroxidase conjugated IgG (0.2 mg vial)
SAFVII-APBIO – Sheep anti human Factor VII, affinity purified, Biotinylated IgG (0.1 mg vial)
SAFVII-AP – Sheep anti human Factor VII, affinity purified IgG (0.5 mg vial)
SAFVII-APFTC – Sheep anti human Factor VII, affinity purified, FITC conjugated IgG (0.1 mg vial)
FVII-AG – Complete Factor VII Antigen ELISA Kit – 1 plate/kit
FVII-EIA – Factor VII Paired Antibody Set – 5 plate set
Description of Factor VII
Factor VII (FVII, also known as Stable Factor and Proconvertin) is a vitamin K-dependent glycoprotein produced in the liver. Plasma concentration of FVII is normally ~0.5 μg/ml (10 nM) in plasma. A deficiency of FVII is associated with bleeding in a clinical pattern similar to haemophilia, but is inherited as an autosomal recessive trait. The deficiency can be characterized by a quantitative (low activity and low antigen) or a qualitative (low activity and normal antigen) defect in FVII function. In its zymogen form FVII is a single chain molecule of ~50 kDa. It contains two EGF-like domains and an amino-terminal domain containing 10 γ-carboxyglutamic acid (Gla) residues. These Gla residues allow FVII to bind divalent metal ions and participate in calcium-dependent binding interactions. FVII and activated FVII (FVIIa) bind to tissue factor exposed at the site of vascular injury. FIXa, FXa or FVIIa rapidly activate tissue factor-bound FVII to FVIIa in the presence of calcium and phospholipid. Thrombin and FXIIa are able to activate FVII in the fluid phase in the absence of cofactors. The activation of the single chain zymogen FVII occurs by proteolysis after residue Arg152, resulting in a two-chain active serine protease consisting of a 30 kDa heavy chain and a 18 kDa light chain. In complex with tissue factor, phospholipid and calcium, FVIIa is able to activate F.X and F.IX. Free FVIIa in plasma is remarkably stable, but the activity of FVIIa/TF complex is regulated by Tissue Factor Pathway Inhibitor (TFPI) in the presence of F.Xa, and also by Antithrombin (ATIII) in the presence of heparin1-3.
References and Reviews
1. Rao LVM, Bajaj SP, Rapaport SI; Activation of Human Factor VII During Clotting in Vitro; Blood 65, pp 218-226, 1985.
2. Lawson, JH, Butenas S, Ribarik N, Mann KG; Complex-dependent Inhibition of Factor VIIa by Antithrombin III and Heparin; JBC 268 pp 767-770, 1993.
3. Nemerson Y, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 81-93, J.B. Lippincott Co., Philadelphia PA, USA, 1994.